View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 7, 2011

BioLineRx Enrols First Patient for Neuropathic Drug Phase I Study

BioLineRx has enrolled the first patient in a Phase I study of BL-1021, an oral drug to treat neuropathic pain. The first-in-human, single-site, double-blind and placebo-controlled study will evaluate the safety, tolerability and pharmacokinetics of single or multiple doses of BL-1021

By cms admin

BioLineRx has enrolled the first patient in a Phase I study of BL-1021, an oral drug to treat neuropathic pain.

The first-in-human, single-site, double-blind and placebo-controlled study will evaluate the safety, tolerability and pharmacokinetics of single or multiple doses of BL-1021 in healthy volunteers.

The study, carried out by professor Yoseph Caraco at the Hadassah Clinical Research Center, is expected to enrol up to 56 people.

Preclinical studies have shown that BL-1021 has a lowered propensity for sedation, no cardiac toxicity and improved efficacy compared with other anti-pain medications.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology